PATENT CLAIM ANALYSIS

Application Number: 16227266
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-04
Patent Classification: ["424", "130100"]

Abstract:
Use of antagonists to IL-31 are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.

Claim (Index 3):
The method of  claim 2 , wherein the isotype of the humanized monoclonal antibody is IgG4.

Metadata:
- Claim Count in Document: 7.0
- Percentile: 98.0
- Lexical Diversity: 1.41463
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['12395095', '13788454', '12607831', '15461090', '13075845']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7632675392360833
- 35 USC 102 Novelty (BERT): 0.5603828877823948
- Combined Prediction Score: 0.7429790740907144
- Mean Citation Score: 336.5395220000001
- Max Citation Score: 443.72058
- Similarity Product: 360.1492108336973

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test